StockData
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. (SGMT) stock

SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$9.85−0.28 (-2.76%)

Close on Nov 17, 2026Market cap $612.26MP/E –Yield –

Sagimet Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Sagimet Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$52.63M. For fiscal 2025 it was -$56.89M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$56.89M–
FY2024Dec 31, 2024-$54.45M–
FY2023Dec 31, 2023-$30.74M–
FY2022Dec 31, 2022-$31.06M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.82M–
Q1 FY2026Mar 31, 2026-$11.71M–
Q4 FY2025Dec 31, 2025-$10.77M–
Q3 FY2025Sep 30, 2025-$14.33M–
Q2 FY2025Jun 30, 2025-$11.93M–
Q1 FY2025Mar 31, 2025-$19.87M–
Q4 FY2024Dec 31, 2024-$18.20M–
Q3 FY2024Sep 30, 2024-$16.90M–
Q2 FY2024Jun 30, 2024-$10.59M–
Q1 FY2024Mar 31, 2024-$8.77M–
Q4 FY2023Dec 31, 2023-$9.47M–
Q3 FY2023Sep 30, 2023-$7.45M–
Q2 FY2023Jun 30, 2023-$7.06M–
Q1 FY2023Mar 31, 2023-$6.77M–
Q4 FY2022Dec 31, 2022-$7.39M–
Q3 FY2022Sep 30, 2022-$7.69M–
Q2 FY2022Jun 30, 2022-$7.24M–

More Sagimet Biosciences figures

See a number that looks wrong?